ESTRO 2024 - Abstract Book

S1907

Clinical - Mixed sites, palliation

ESTRO 2024

Keywords: Carbon ion, Radiotherapy, Indications

References:

1. Ebner D K, Kamada T. The emerging role of carbon-ion radiotherapy. Frontiers in Oncology. 2016;6:140.

2. Malouff T D, Mahajan A, Krishnan S, Beltran C, Seneviratne D S, Trifiletti D M. Carbon Ion Therapy: A Modern Review of an Emerging Technology. Frontiers in Oncology. 2020;10:82.

3. Valable S, Gérault A N, Lambert G, Leblond M M, Anfray C, Toutain J et al. Impact of Hypoxia on Carbon Ion Therapy in Glioblastoma Cells: Modulation by LET and Hypoxia-Dependent Genes. Cancers. 2020;12(8):2019.

4. Kirkby K J, Kirkby N F, Burnet N G, Owen H, Mackay R I, Crellin A ET AL. Heavy charged particle beam therapy and related new radiotherapy technologies: The clinical potential, physics and technical developments required to deliver benefit for patients with cancer. British Journal of Radiology. 2020;93(1116):20200247

1215

Poster Discussion

Oligometastatic Mesothelioma treated with Ablative Radiotherapy (OMAR): multi-institutional database

Davide Franceschini 1 , Maria Ausilia Teriaca 1 , Ciro Franzese 1,2 , Paolo Ghirardelli 3 , Elisabetta Parisi 4 , Gaia Piperno 5 , Matteo Sepulcri 6 , Marco Krengli 7 , Barbara Jereczec-Fossa 5,8 , Antonino Romeo 4 , Vittorio Vavassori 3 , Alessio Bruni 9 , Nicolaus Andratschke 10 , Matthias Guckenberger 10 , Giovanni Luca Ceresoli 11 , Marta Scorsetti 1,2 1 IRCCS-Humanitas Research Hospital, Radiotherapy and Radiosurgery, Rozzano, Italy. 2 HUMANITAS University, Biomedical sciences, Pieve Emanuele, Italy. 3 Cliniche Humanitas Gavazzeni, Radiotherapy, Bergamo, Italy. 4 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Radiotherapy, Meldola, Italy. 5 European Institute of Oncology (IEO)-IRCCS, Radiotherapy, Milan, Italy. 6 Veneto Institute of Oncology-IOV-IRCCS, Radiotherapy, Padova, Italy. 7 Università di Padova e Istituto Oncologico Veneto, DISCOG, Padova, Italy. 8 University of Milan, Oncology and Hemato-oncology, Milan, Italy. 9 University Hospital of Modena, Radiotherapy, Modena, Italy. 10 University Hospital Zurich, Radiotherapy, Zurich, Switzerland. 11 Cliniche Humanitas Gavazzeni, Medical Oncology, Bergamo, Italy

Purpose/Objective:

Pleural mesothelioma (PM) still has a dismal prognosis. Local and distant recurrences are common and effective systemic therapies are scarce. In case of localized recurrent disease even after initial multimodal treatment, standardized treatment recommendations for effective salvage strategies treatment are needed. Stereotactic Ablative Radiotherapy (SABR) is emerging as a valid alternative to surgery in the oligometastatic setting, although robust data are lacking in PM due to the rarity of the disease. The aim of this retrospective multicentric study is to evaluate whether SABR can have an impact on disease course in patients with unresectable PM with radiological progression after ≥ 1 line of chemotherapy at a maximum of 3 pleural (or extrapleural) sites.